Reviewing Quanterix Corporation (QTRX)’s and Menlo Therapeutics Inc. (NASDAQ:MNLO)’s results

This is therefore a contrasting of the institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation in Quanterix Corporation (NASDAQ:QTRX) and Menlo Therapeutics Inc. (NASDAQ:MNLO). The two are both Biotechnology companies that compete with one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Quanterix Corporation 33.34M 14.71 30.40M -2.07 0.00
Menlo Therapeutics Inc. 13.41M 11.01 43.13M -1.73 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Quanterix Corporation and Menlo Therapeutics Inc.


Table 2 provides the return on equity, net margins and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Quanterix Corporation -91.18% -53.8% -37.5%
Menlo Therapeutics Inc. -321.63% -41.7% -30.3%


Quanterix Corporation’s Current Ratio and Quick Ratio are 4.1 and 3.8 respectively. The Current Ratio and Quick Ratio of its competitor Menlo Therapeutics Inc. are 19.2 and 19.2 respectively. Menlo Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Quanterix Corporation.

Institutional & Insider Ownership

Roughly 68.6% of Quanterix Corporation shares are owned by institutional investors while 77.8% of Menlo Therapeutics Inc. are owned by institutional investors. 11.9% are Quanterix Corporation’s share owned by insiders. Competitively, Menlo Therapeutics Inc. has 19.12% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Quanterix Corporation 6.51% 14.84% 28.61% 18.88% 14.25% -7.03%
Menlo Therapeutics Inc. -8.32% -22.5% -31.38% -29.27% 0% -80.81%

For the past year Quanterix Corporation was less bearish than Menlo Therapeutics Inc.


On 6 of the 10 factors Quanterix Corporation beats Menlo Therapeutics Inc.

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and SR-X system that supports the detection capability of approximately six biomarkers per test. The company's products also comprise kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, assay development, and custom development services. Quanterix Corporation primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Lexington, Massachusetts.

Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis. It is also developing products that are in Phase II clinical trials to treat pruritus associated with psoriasis, atopic dermatitis, and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is headquartered in Redwood City, California.